Fukada, Junichi

写真a

Affiliation

School of Medicine, Department of Radiology (Radiation Oncology) (Shinanomachi)

Position

Assistant Professor/Senior Assistant Professor

External Links

Career 【 Display / hide

  • 1999.05
    -
    2001.04

    慶應義塾大学医学部, 放射線科, 研修医

  • 2001.05
    -
    2002.05

    慶應義塾大学医学部, 放射線科, 助手(専修医)

  • 2002.06
    -
    2002.09

    慶應義塾大学医学部, 放射線科, 助手

  • 2002.10
    -
    2004.10

    国立病院東京医療センター, 放射線科, レジデント

  • 2004.11
    -
    2007.03

    慶應義塾大学医学部, 放射線科, 助手

display all >>

Academic Background 【 Display / hide

  • 1999.03

    慶應義塾大学, 医学部

    Graduated

Academic Degrees 【 Display / hide

  • 博士(医学), 慶應義塾大学, 2012.12

 

Papers 【 Display / hide

  • Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: A long-term follow-up study

    Endo Y., Kitago M., Aiura K., Shinoda M., Yagi H., Abe Y., Oshima G., Hori S., Nakano Y., Itano O., Fukada J., Masugi Y., Kitagawa Y.

    World Journal of Surgical Oncology (World Journal of Surgical Oncology)  17 ( 1 )  2019.08

     View Summary

    © 2019 The Author(s). Background: We aimed to evaluate the efficacy and safety of 5-fluorouracil-based neoadjuvant chemoradiotherapy (NACRT) in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC). Methods: This retrospective study investigated the clinicopathological features and > 5-year survival of patients with T3/T4 PDAC who underwent NACRT at our institute between 2003 and 2012. Results: Seventeen resectable and eight borderline resectable patients were included. The protocol treatment completion and resection rates were 92.0% and 68.0%, respectively. Two patients failed to complete chemotherapy owing to cholangitis or anorexia. Common grade 3 toxicities included anorexia (12%), neutropenia (4%), thrombocytopenia (4%), anemia (4%), and leukopenia (12%). Pathologically negative margins were achieved in 94.1% of patients who underwent pancreatectomy. Pathological response according to Evans' classification was grade IIA in 10 patients (58.8%), IIB in 5 patients (29.4%), and IV in 2 patients (11.8%). Postoperative pancreatic fistulas were observed in four patients (23.5%), delayed gastric emptying in one patient (5.9%), and other operative morbidities in four patients (23.5%). The 1-, 2-, 5-, and 10-year overall survival rates were 73.9%, 60.9%, 60.9%, and 39.1%, respectively (median follow-up period, 80.3 months). Conclusions: NACRT is tolerable and beneficial for resectable/borderline resectable PDAC, even in the long-term.

  • A Highly Advanced Gastric Cancer Maintaining a Clinical Complete Response after Chemoradiotherapy Comprising S-1 and Cisplatin

    Yura M., Takahashi T., Fukuda K., Nakamura R., Wada N., Fukada J., Kawakubo H., Takeuchi H., Shigematsu N., Kitagawa Y.

    Case Reports in Gastroenterology (Case Reports in Gastroenterology)  12 ( 3 ) 578 - 585 2018.09

     View Summary

    © 2018 The Author(s). Published by S. Karger AG, Basel. We report a patient with highly advanced gastric carcinoma who was treated successfully with chemoradiotherapy (CRT) comprising S-1 and cisplatin. The patient was a 71-year-old male who was diagnosed with advanced gastric carcinoma by esophagogastroduodenoscopy (EGD) by medical examination. EGD demonstrated type 3 advanced gastric carcinoma in the posterior wall of the upper gastric body. An abdominal computed tomography (CT) scan showed that the gastric wall was thickened due to gastric primary tumor, and large lymph nodes (LNs) including the lesser curvature LN, anterosuperior LN along the common hepatic artery and some para-aortic LNs were detected. The patient was diagnosed with stage IV advanced gastric carcinoma according to the Japanese classification of gastric carcinoma (cT4a, cN3, cM1 [para-aortic LN], cStage IV). Preoperative CRT was carried out in an attempt to downstage the disease. Remarkable reduction of the primary tumor and metastatic LNs was observed after initial CRT, and radiological examination determined that a partial response had been achieved. Adverse effects included grade 2 anorexia and grade 3 ALP elevation (919 U/ml). No grade 4 or more severe adverse event was observed. After CRT, although we recommended curative surgery, the patient refused surgical treatment and opted for conservative treatment. Thus, we continued S-1 oral administration for 1 year. Five months after beginning CRT, upper endoscopy showed that the tumor had maintained regression and scar formation, in which no cancer cells were detected by endoscopic biopsy. The patient is doing well and has maintained a clinical complete response for more than 42 months without curative surgery. CRT could be considered as an option for treatment of patients with locally advanced gastric carcinoma diagnosed as unresectable, or for those who refuse surgical treatment.

  • Fatal Intracranial Hemorrhage Due to Thrombocytopenia in a Patient With Castration-Resistant Prostate Cancer Showing Extensive Bone Uptake of Injected Ra-223 Dichloride

    Nakahara, Tadaki, Owaki, Yoshiki, Kosaka, Takeo, Fukada, Junichi, Ichimura, Akira, Jinzaki, Masahiro

    CLINICAL NUCLEAR MEDICINE (Clinical Nuclear Medicine)  43 ( 7 ) 546 - 547 2018.07

    Research paper (scientific journal),  ISSN  0363-9762

     View Summary

    © 2018 Wolters Kluwer Health, Inc. All rights reserved. A 64-year-old man with castration-resistant prostate cancer received 223Ra injection to treat bone metastases. The patient underwent a 223Ra SPECT scan after the first 223Ra injection in which there was increased uptake all over the spine. Spine-to-background activity ratio in the patient was approximately three times greater than normal spine-to-background activity ratios in 223Ra SPECT obtained from the other patients. Eight days after the fifth injection, the patient exhibited a very poor neurologic examination and died of intracranial hemorrhage due to severe thrombocytopenia (platelet counts, 23,000/mm3). The extensive radiation to the spine may have enhanced myelophthisic process in this case.

  • Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma

    Kumabe, A., Fukada, J., Kota, R., Koike, N., Shiraishi, Y., Seki, S., Yoshida, K., Kitagawa, Y., Shigematsu, N.

    DISEASES OF THE ESOPHAGUS (Diseases of the Esophagus)  31 ( 4 ) 546 - 547 2018.04

    Research paper (scientific journal),  ISSN  1442-2050

     View Summary

    © The Author(s) 2017. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. We investigated long-term treatment outcomes and the feasibility of chemoradiotherapy consisting of daily-low-dose 5-fluorouracil and cisplatin (LDFP) chemotherapy plus radiotherapy for Stage I-II squamous cell esophageal cancer. Treatment records from the 2000 through 2008 period were reviewed retrospectively. Fractionated radiotherapy was performed with a total dose of 60 Gy delivered in 2 Gy per fraction. LDFP chemotherapy, as continuous infusion of 200 mg/m 2 5-fluorouracil combined with one hour infusion of 4 mg/m 2 cisplatin, was administered on the same days as radiotherapy. Survival was calculated by the Kaplan-Meier method. Survival, responses, failure patterns, and toxicities were evaluated. Seventy-six (47 stage I and 29 stage II) patients were analyzed with a median follow-up of 93.6 months. The 8-year overall survival (OS), progression-free survival (PFS) and cause-specific survival (CSS) rates were 63.4%, 49.8%, and 76.7%, respectively. The 8-year OS, PFS, and CSS for stage I and stage II patients were 71.0%/56.1%/82.9% and 45.2%/40.2%/66.6%, respectively. Sixty-eight patients (89.5%) completed the treatment regimen. A complete response (CR) was achieved in 68 patients (89.5%). Twenty-five patients (36.8%) experienced recurrence after CR. The failure patterns were (overlap included): local failure (n = 12), nodal metastasis (n = 12), distant metastasis (n = 3), details unknown (n = 2). Salvage therapy was performed for local failure; endoscopic therapy (n = 7) or surgery (n = 2). Six patients remain alive without relapse after salvage endoscopic therapy. Major Grade 3 or higher acute adverse events were leukopenia (22%), anorexia (17%), and esophagitis (11%). Major late toxicities (Grade 3 or 4) involved pericardial effusion (12%), pleural effusion (4%), and esophageal stenosis (3%). Chemoradiotherapy with LDFP provided favorable long-term survival with acceptable toxicity for Stage I-II squamous cell esophageal cancer. The tumor response was excellent, but close endoscopic follow-up is essential for detecting and treating local recurrence.

  • Synovial sarcoma of the maxillary sinus: an extremely rare case with excellent response to chemotherapy

    Saito, Shin, Ozawa, Hiroyuki, Ikari, Yuuichi, Nakahara, Nana, Ito, Fumihiro, Sekimizu, Mariko, Fukada, Junichi, Kameyama, Kaori, Ogawa, Kaoru

    ONCOTARGETS AND THERAPY (OncoTargets and Therapy)  11   483 - 488 2018

    Research paper (scientific journal),  ISSN  1178-6930

     View Summary

    © 2018 Saito et al. This paper presents an extremely rare case of synovial sarcoma arising from the maxillary sinus, which resulted in a clinically complete response to chemotherapy. Synovial sarcoma is a rare soft tissue malignant tumor, most commonly affecting the extremities. While ∼10% occur in the head and neck region, synovial sarcoma of the sinonasal tract is extremely rare, with only 11 cases having been reported previously. As with other sarcomas, the standard treatment is complete resection while allowing for a safe margin, but this is often difficult in the head and neck area due to the complicated anatomy there. This makes the treat­ment of head and neck sarcoma challenging and leads to the need for a multimodal approach in advanced cases. However, the exact efficacy of chemotherapy is not well understood. In this report, we present a case of unresectable maxillary sinus synovial sarcoma that was success­fully treated by chemotherapy followed by radiation therapy. A 53-year-old Japanese man was referred to our hospital with a history of left nose obstruction over the previous couple of years. Computed tomography/magnetic resonance imaging revealed a tumor arising from the maxillary sinus that extended to adjacent tissues. A biopsy was performed, and the tumor was diagnosed as synovial sarcoma. Since the tumor was unresectable, neoadjuvant chemotherapy was administered. The response was excellent, and the tumor became undetectable under endoscopy and radiological imaging. This provided us with a clinical evaluation of “complete response”. The treatment was concluded with definitive radiotherapy and two more cycles of adjuvant chemotherapy. The patient remains free of disease 12 months after treatment. Synovial sarcoma of the head and neck is a rare entity; complete resection is the treatment of choice but (neo)adjuvant chemotherapy can be considered in unresectable cases, as we show here in the present case.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

display all >>

Presentations 【 Display / hide

  • Evaluation of our modified tangential irradiation technique for breast cancer patients using dose volume histogram (DVH)

    Takeda A, Shigematsu N, Kawaguchi O, Kutsuki S, Ishibashi R, Kunieda E, Takeda T, Takemasa K, Ito H, Ohashi T, Fukada J, Yamamoto A, Kubo A

    Scientific Assembly and Anual Meeting of RSNA, 

    2002.12

    Poster presentation

  • Micro multileaf collimator(MMLC)によるRadiosurgery施行時の幾何学的精度測定

    Kunieda Etsuo, Kawaguchi Osamu, Kawase Takatsugu, Fukada Junichi, Shigematsu Naoyuki, Kubo Atsushi, Seguro Seiichi, Kitagawa Isao

    日本放射線腫瘍学会第15回学術大会, 

    2002.11

    Oral presentation (general)

  • 聴神経腫瘍の定位放射線照射における分割照射の優位性

    Kawase Takatsugu, Kunieda Etsuo, Kawaguchi Osamu, Shigematsu Naoyuki, Kutsuki Shouji, Fukada Junichi, Kubo Atsushi

    日本放射線腫瘍学会第15回学術大会, 

    2002.11

    Oral presentation (general)

  • Micro-multileaf Collimator(MMLC)によるradiosurgery

    Kunieda Etsuo, Kawaguchi Osamu, Oohira Takayuki, Onozuka Satoshi, Shigematsu Naoyuki, Fukada Junichi, Takeda Atsuya, Kubo Atsushi

    第11回日本定位放射線治療学会, 

    2002.07

    Oral presentation (general)

  • Dynamic IA-CT angioとMicro-multileaf CollimatorによるAVMのradiosurgery

    Kunieda Etsuo, Kawaguchi Osamu, Fukada Junichi, Shigematsu Naoyuki, Kubo Atsushi

    日本放射線学会関東地方会, 

    2002.06

    Oral presentation (general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 低線量照射における放射線超感受性を用いた低侵襲がん治療戦略の開発-膠芽腫での検討

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • Development of new strategy for glioblastoma focused on low-dose hyper-radiosensitivity

    2014.04
    -
    2017.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

     View Summary

    Glioblastoma is highly lethal disease. Radiotherapy plays important role but tumor recurrence is occurred in most of cases. We focused low-dose hyper-radiosensitivity phenomena as a new treatment strategy. Cell survival, cell cycle and rate of apoptosis were measured. Survival rate decreased in association with increasing dose on single low dose irradiation suggestive of hyper-radiosensitivity in some cell lines. On the other hand, the observed cell cycle change of G1/G2 ratio was less than 5%.
    The survival rate lowered when an interval became longer by low dose repeat irradiation (LDRR). The moderate change of the G1/G2 ratio was observed in the examination 30 minutes after irradiation only at 30 minutes interval. A rise of the apoptotic component was observed at 30 minutes interval. The LDRR at 30 minutes interval seems to be a promising approach, although, confirmation by other technique and elucidation of the further mechanism is warranted.

Awards 【 Display / hide

  • 日本放射線腫瘍学会梅垣賞

    2014.12

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, RADIOLOGY

    2022

  • LECTURE SERIES, RADIOLOGY

    2021

  • LECTURE SERIES, RADIOLOGY

    2020

  • LECTURE SERIES, RADIOLOGY

    2019

Courses Previously Taught 【 Display / hide

  • 臨床実習 放射線科学

    Keio University

    2015.04
    -
    2016.03

  • 系統講義 放射線医学「治療」放射線治療・各論

    Keio University

    2015.04
    -
    2016.03

    Lecture

  • 自主学習

    Keio University

    2015.04
    -
    2016.03

    Laboratory work/practical work/exercise